Pfizer, Inc. (NYSE: PFE) and TransTech Pharma, Inc. have entered into a license agreement to develop and commercialize small and large molecule compounds under development by TransTech.
The said compounds target the receptor for advanced glycation end products (RAGE) which can be potentially used in the treatment of Alzheimer's disease.
The collaboration grants Pfizer the exclusive worldwide rights to develop and commercialize TransTech's portfolio of RAGE modulators: the most advanced being TTP488 (an orally available small-molecule compound that has completed a Phase 2a study in Alzheimer's patients and is currently in a Phase 2 study in patients with diabetic nephropathy) and TTP4000 (a large-molecule compound that is expected to enter Phase 1 clinical trials before the end of 2006).
The terms of agreement include the following:
The said agreement, however, is still subject to clearance by the U.S. Federal Trade Commission.
Read more details from the Pfizer press release.
Comment Preview